Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings
T-DXd demonstrated notable efficacy and a manageable safety profile in patients with HER2-positive AGC. Rapid and deep tumor shrinkage may have a significant impact on survival.
Authors
- Mikako Tamba (ORCID: https://orcid.org/0009-0006-1380-4325)
- Akira Ooki (ORCID: https://orcid.org/0000-0001-7618-5775)
- Keitaro Shimozaki (ORCID: https://orcid.org/0000-0002-4559-5699)
- Hiroki Osumi (ORCID: https://orcid.org/0000-0002-4742-0446)
- Koichiro Yoshino (ORCID: https://orcid.org/0000-0002-9877-9336)
- Takeru Wakatsuki (ORCID: https://orcid.org/0000-0002-1463-3859)
- Shohei Udagawa (ORCID: https://orcid.org/0009-0005-2225-7346)
- Mariko Ogura (ORCID: https://orcid.org/0000-0002-1004-8425)
- Koshiro Fukuda (ORCID: https://orcid.org/0000-0003-0464-8923)
- Kensei Yamaguchi (ORCID: https://orcid.org/0000-0001-6887-5709)
- Eiji Shinozaki (ORCID: https://orcid.org/0000-0003-1831-0536)
- Shota Fukuoka
- Keisho Chin
Institutions
- Japanese Foundation For Cancer Research (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1177/17562848251333538
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.52